ICRF-187 permits longer treatment with doxorubicin in women with breast cancer - Wikidata - awgldk - TriplyDB

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

http://www.wikidata.org/entity/Q28324350

about

Cardioprotective interventions for cancer patients receiving anthracyclines Cardioprotective interventions for cancer patients receiving anthracyclines Cardiotoxicity in childhood cancer survivors: strategies for prevention and management Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187 Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials Iron-mediated cardiovascular injury.Cardiotoxicity of cancer therapy.Dexrazoxane for the treatment of chemotherapy-related side effects.Chemotherapy-induced cardiotoxicity.Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.Cardiovascular toxicities from systemic breast cancer therapy.Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.Early identification of anthracycline cardiomyopathy: possibilities and implications.Cardiotoxic effects of anthracycline-taxane combinations.Hodgkin's lymphoma. II: Treatment and delayed morbidity.A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells.Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in mice Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer Progression-free survival as a surrogate endpoint in advanced breast cancer Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Anthracycline cardiotoxicity.The role of antioxidants in the era of cardio‑oncology.Prevention of cardiotoxicity among survivors of childhood cancer.Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Chemotherapy-induced cardiotoxicity in children.Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity.Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death.The role of iron and iron chelators in anthracycline cardiotoxicity.Observational studies: goldmines of information on rare diseases.Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.Preventing the cardiotoxicity of anthracyclines by dexrazoxane Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.Resveratrol: a novel type of topoisomerase II inhibitor.Oxidative Stress and Cellular Response to Doxorubicin: A Common Factor in the Complex Milieu of Anthracycline Cardiotoxicity.

P2860

Q24236338-BB3BC987-D8E7-4B1B-9EB0-3F3E38AA7850 Q24243021-DD3DF8A2-2237-4B1C-91C0-215BF809426A Q24628695-0B2BC5F8-C744-4E1B-9D4D-1039B5DCF76B Q28378716-D21D17DD-08FD-4935-B0B9-F32376F6C956 Q28379015-662C6420-F46B-4688-9FF4-ED5E73C50017 Q33619867-1D5137DE-BA4F-4251-BBA7-DCFF092D9C1F Q33687605-D2E52725-2E13-49DC-9BD8-807375CCFFB1 Q33704056-3688F6A2-D1B7-4DFE-BAB2-80B8CAD3DF06 Q34211957-D7A177DE-CCBD-4D01-86D4-0A19C04CDBC9 Q34258080-90E8243C-E5B7-481B-B154-07CC21ED423B Q34269228-4196AA96-7069-425C-B508-BE9589F92872 Q34630349-260A9280-F19B-47B4-B21C-3FE8F5EF8780 Q34659375-BAAEC0E6-4BC0-4B17-88B6-908DABFF8D05 Q34800157-056B5794-6ADF-4676-B32C-F4321D03522B Q35194442-2B7B6798-9E2D-4F20-92AF-0526F2FE4933 Q35662615-EC26C7BE-E388-4FDA-973B-93F42B9FD5F3 Q35753383-CF293AC2-FF27-4746-9055-A6E22B4FC283 Q35862550-2093A70E-3885-415C-974C-AD937FE69A90 Q36030052-7B932E2D-551E-458C-AF83-FE78D3C83D1E Q36053116-5857BB13-01DD-4004-A38F-3258BF464BC4 Q36097717-F32AE1D1-6CF2-4891-96EC-26CB332A0C3B Q36309823-B0707E56-AAA1-49C1-B58B-0A5A738DD8B0 Q36552307-87DB63FA-311F-4120-8F59-927C44F40C00 Q36568908-15C5F258-AE5E-496C-8606-6F27F4DEBB3E Q36624983-89AD6438-B3C4-4D65-B084-B2A0CC3B906F Q37626273-7A707763-D906-4A82-9BC6-4A7EEE56A9C6 Q38824644-0025B91A-C2B0-4E86-AF17-2265A0B86EA3 Q38838517-CD895820-22C7-4A1B-8B7C-AC1A69984F30 Q39415815-1F7A4241-F160-41C4-B90C-5A9A472D9857 Q40558168-13C15AA9-4463-421A-B13C-00F8B54BB083 Q40598968-A19A6116-E87F-4280-BD5D-6301934453AE Q40790446-1B01720A-F04E-4140-9083-4A955A71BF73 Q42352177-D78B5A67-C6D0-4496-97E0-D8D2CF4946F9 Q42537936-E98366BE-95F4-41BA-A7A4-DBB6F380C69A Q42764756-7070CBBD-2723-4052-B798-B0DD7A505E0F Q43869754-EA7BF2EF-C04E-430C-BEA1-1B1A468CE7C9 Q44391942-75FF595C-5D83-48DC-B7E3-A5A7BCC2DA70 Q45073135-7DFB5839-9463-4F24-8003-A7A67FA2B290 Q46241633-CD5FE6D5-D577-44A6-A016-DE865EEB98FB Q46253112-DC0918F5-1984-48A6-949A-C79FCEA64A2C

P2860

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

http://www.wikidata.org/entity/Q28324350

description

1992 nî lūn-bûn

@nan

1992 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年論文

@yue

1992年論文

@zh-hant

1992年論文

@zh-hk

1992年論文

@zh-mo

1992年論文

@zh-tw

1992年论文

@wuu

name

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@ast

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@en

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@nl

type

label

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@ast

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@en

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@nl

prefLabel

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@ast

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@en

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@nl

P1433

Q28324350-F6F90755-7096-420E-A990-15712D4B0AE0

P1476

Q28324350-8BB78F54-B2E0-43F9-B333-206CA62E2719

P2093

Q28324350-15E22308-964A-4748-B7F4-67AD0117964B

Q28324350-2C471839-0661-4420-8B9B-0D4D4938B911

Q28324350-4E5A3769-045D-4277-BB79-611B9721EE4B

Q28324350-7FA542A1-4D08-4B55-963C-D3406CE0F7C3

Q28324350-9582773A-033A-4470-93F5-A744B6BC692D

Q28324350-A27A709F-D4A9-4674-BC9A-96285B67D4D9

Q28324350-B8D598D0-2B46-4A8F-A8E5-9A1AC5A35C63

Q28324350-C65E9AF4-B6FC-4333-8B59-F5E5BF0E0CE5

Q28324350-DC446418-8D64-4DB9-9410-DFBDD1B6CE25

Q28324350-FC56D330-6CED-4C8F-B4A8-18CB986E5DC8

P304

Q28324350-5BDC132F-1802-4E99-893D-E2D26624D558

P31

Q28324350-2B362F10-05CC-4BF0-83C9-E3D4166850A8

P356

Q28324350-14B60AA3-FA5E-46AE-A3C6-E3450FE6331F

P407

Q28324350-BCA9F6A5-C555-4A8C-AAE0-AFCD2F647968

P433

Q28324350-28B0C786-5EBF-40D2-AF5C-342358DF437C

P478

Q28324350-64E7F8F8-657A-450C-AE5E-FA700EE5CB84

P577

Q28324350-E2BB9375-AA88-469E-B641-0F4F5FA9F383

P698

Q28324350-A6E1509E-84C9-48C6-AAA1-F19E40DBB24B

P356

JCO.1992.10.1.117

P1433

Journal of Clinical Oncology

P1476

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

@en

P2093

A Zeleniuch-Jacquotte

http://www.w3.org/2001/XMLSchema#string

E Kramer

http://www.w3.org/2001/XMLSchema#string

H Hochster

http://www.w3.org/2001/XMLSchema#string

J C Wernz

http://www.w3.org/2001/XMLSchema#string

J L Speyer

http://www.w3.org/2001/XMLSchema#string

J Sanger

http://www.w3.org/2001/XMLSchema#string

M D Green

http://www.w3.org/2001/XMLSchema#string

M Meyers

http://www.w3.org/2001/XMLSchema#string

M Rey

http://www.w3.org/2001/XMLSchema#string

V Ferrans

http://www.w3.org/2001/XMLSchema#string

P304

117-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.1992.10.1.117

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

1992-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1727913

http://www.w3.org/2001/XMLSchema#string